Press Releases

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that Director and…

Move aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…

Data establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the…

Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial…

Patent-protected methylone-inspired analogs support pipeline expansion into PTSD CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric…

EB-003 significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) indicating a positive therapeutic effect in well-established translational rodent model for PTSD CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB)…

EB-003 revealed to also act as an agonist of the serotonin receptor 5-HT1B, a validated target of drugs approved to treat major depressive disorder and a variety of neurological conditions…

CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological…

Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small…

New Intellectual Property Unlocks Potential for Sleep and CNS Therapeutics CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel…